143 related articles for article (PubMed ID: 36657414)
1. Sudden lymphoid blast crisis after tyrosine kinase inhibitor discontinuation in chronic phase chronic myeloid leukemia: cautionary tales for appropriate molecular monitoring.
Bataller A; Haddad FG; Issa GC; Sasaki K; Jabbour E; Borthakur G; Ferrajoli A; Short NJ
Leuk Lymphoma; 2023 Mar; 64(3):746-749. PubMed ID: 36657414
[No Abstract] [Full Text] [Related]
2. Chronic Myeloid Leukemia, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology.
Shah NP; Bhatia R; Altman JK; Amaya M; Begna KH; Berman E; Chan O; Clements J; Collins RH; Curtin PT; DeAngelo DJ; Drazer M; Maness L; Metheny L; Mohan S; Moore JO; Oehler V; Pratz K; Pusic I; Rose MG; Shomali W; Smith BD; Styler M; Talpaz M; Tanaka TN; Tantravahi S; Thompson J; Tsai S; Vaughn J; Welborn J; Yang DT; Sundar H; Gregory K
J Natl Compr Canc Netw; 2024 Feb; 22(1):43-69. PubMed ID: 38394770
[TBL] [Abstract][Full Text] [Related]
3. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome.
Druker BJ; Sawyers CL; Kantarjian H; Resta DJ; Reese SF; Ford JM; Capdeville R; Talpaz M
N Engl J Med; 2001 Apr; 344(14):1038-42. PubMed ID: 11287973
[TBL] [Abstract][Full Text] [Related]
4. Omacetaxine Mepesuccinate for Chronic Myeloid Leukemia.
Rosshandler Y; Shen AQ; Cortes J; Khoury HJ
Expert Rev Hematol; 2016 May; 9(5):419-24. PubMed ID: 26853281
[TBL] [Abstract][Full Text] [Related]
5. Optimal timing of molecular monitoring after tyrosine kinase inhibitor discontinuation in chronic myeloid leukemia.
Tiribelli M; Toffoletti E; Di Giusto S; Fanin R; Damiani D
Eur J Haematol; 2023 Mar; 110(3):330-331. PubMed ID: 36458956
[No Abstract] [Full Text] [Related]
6. T-lymphoid or T/myeloid blast phase of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy: a report of 14 cases.
Gong Z; Xie W; Wang W; Chen Z; Xu J; Yuan J; Zhou Y; Wang D; Medeiros LJ; Hu S
Int J Lab Hematol; 2017 Apr; 39(2):e45-e50. PubMed ID: 27863007
[No Abstract] [Full Text] [Related]
7. Deep molecular responses for treatment-free remission in chronic myeloid leukemia.
Dulucq S; Mahon FX
Cancer Med; 2016 Sep; 5(9):2398-411. PubMed ID: 27367039
[TBL] [Abstract][Full Text] [Related]
8. Blast crisis of chronic myeloid leukemia with plasmacytoid dendritic cell phenotype associated with a rare fusion transcript, e13a3 BCR-ABL1.
Xu D; Claudiani S; Naresh K; Mucklow S; Neelakantan P; Yebra E; Apperley JF; Khorashad J; Milojkovic D
Leuk Lymphoma; 2019 Dec; 60(12):3090-3091. PubMed ID: 31184233
[No Abstract] [Full Text] [Related]
9. Differential impact of additional chromosomal abnormalities in myeloid vs lymphoid blast phase of chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy.
Chen Z; Cortes JE; Jorgensen JL; Wang W; Yin CC; You MJ; Jabbour E; Kantarjian HM; Medeiros LJ; Hu S
Leukemia; 2016 Jul; 30(7):1606-9. PubMed ID: 26837843
[No Abstract] [Full Text] [Related]
10. Analysis of ABL kinase domain mutations conferring resistance to tyrosine kinase inhibitors in chronic myeloid leukemia cases from India.
Bagadi S; Saikia T; Pany A; Das B
Clin Lab; 2011; 57(7-8):619-23. PubMed ID: 21888027
[TBL] [Abstract][Full Text] [Related]
11. Fine-tuning of frontline tyrosine kinase inhibitor (TKI) therapy in chronic-phase chronic myeloid leukemia: The choice of the right TKI for the right patient.
Nuhoğlu Kantarcı E; Tolgay E; Eşkazan AE
Cancer; 2023 Sep; 129(17):2610-2612. PubMed ID: 37395503
[No Abstract] [Full Text] [Related]
12. Deep molecular response in patients with chronic phase chronic myeloid leukemia treated with the plasminogen activator inhibitor-1 inhibitor TM5614 combined with a tyrosine kinase inhibitor.
Takahashi N; Kameoka Y; Onizuka M; Onishi Y; Takahashi F; Dan T; Miyata T; Ando K; Harigae H
Cancer Med; 2023 Feb; 12(4):4250-4258. PubMed ID: 36151699
[TBL] [Abstract][Full Text] [Related]
13. B-Lymphoid Blast Phase-Chronic Myeloid Leukemia: Current Therapeutics.
Yohannan B; George B
Int J Mol Sci; 2022 Oct; 23(19):. PubMed ID: 36233138
[TBL] [Abstract][Full Text] [Related]
14. How has treatment changed for blast phase chronic myeloid leukemia patients in the tyrosine kinase inhibitor era? A review of efficacy and safety.
Perrone S; Massaro F; Alimena G; Breccia M
Expert Opin Pharmacother; 2016 Aug; 17(11):1517-26. PubMed ID: 27231757
[TBL] [Abstract][Full Text] [Related]
15. Disappearance of Ph1 chromosome with intensive chemotherapy and detection of minimal residual disease by polymerase chain reaction in a patient with blast crisis of chronic myelogenous leukemia.
Honda H; Miyagawa K; Endo M; Takaku F; Yazaki Y; Hirai H
Int J Hematol; 1993 Jun; 57(3):221-7. PubMed ID: 8364186
[TBL] [Abstract][Full Text] [Related]
16. Pediatric chronic myeloid leukemia with myeloid blast crisis and complex karyotype at presentation.
Sazawal S; Singh K; Chhikara S; Chaubey R; Mishra P; Seth T; Saxena R
Indian J Cancer; 2020; 57(3):343-345. PubMed ID: 32769290
[No Abstract] [Full Text] [Related]
17. A novel insertion mutation of K294RGG within BCR-ABL kinase domain confers imatinib resistance: sequential analysis of the clonal evolution in a patient with chronic myeloid leukemia in blast crisis.
Sakai K; Ishikawa Y; Mori Y; Kobayashi M; Iriyama C; Ozawa Y; Suzuki T; Minami Y; Ishikawa K; Kaneda N; Naoe T; Kiyoi H
Int J Hematol; 2011 Feb; 93(2):237-242. PubMed ID: 21264552
[TBL] [Abstract][Full Text] [Related]
18. Clinical efficacy of second generation tyrosine kinase inhibitor and 5-azacytidine combination in chronic myelogenous leukaemia in myeloid blast crisis.
Ghez D; Micol JB; Pasquier F; Auger N; Saada V; Spentchian M; Ianotto JC; Bourhis JH; Bennaceur-Griscelli A; Terré C; Castaigne S; Rigaudeau S; Rousselot P; de Botton S
Eur J Cancer; 2013 Nov; 49(17):3666-70. PubMed ID: 23968731
[TBL] [Abstract][Full Text] [Related]
19. Molecular analysis of a CML patient with a long duration of chronic phase before and after lymphoid blast crisis.
Price CM; Foadi MD; Morgan GJ; Wiedemann LM
Leukemia; 1990 Jun; 4(6):455-7. PubMed ID: 2359347
[TBL] [Abstract][Full Text] [Related]
20. Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study.
Sawyers CL; Hochhaus A; Feldman E; Goldman JM; Miller CB; Ottmann OG; Schiffer CA; Talpaz M; Guilhot F; Deininger MW; Fischer T; O'Brien SG; Stone RM; Gambacorti-Passerini CB; Russell NH; Reiffers JJ; Shea TC; Chapuis B; Coutre S; Tura S; Morra E; Larson RA; Saven A; Peschel C; Gratwohl A; Mandelli F; Ben-Am M; Gathmann I; Capdeville R; Paquette RL; Druker BJ
Blood; 2002 May; 99(10):3530-9. PubMed ID: 11986204
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
